Contrasting Spyre Therapeutics (NASDAQ:SYRE) and Caribou Biosciences (NASDAQ:CRBU)

Caribou Biosciences (NASDAQ:CRBU) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Caribou Biosciences and Spyre Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	0	0	3	0	3.00
Spyre Therapeutics	0	0	5	2	3.29

Caribou Biosciences currently has a consensus target price of $6.67, indicating a potential upside of 256.51%. Spyre Therapeutics has a consensus target price of $53.40, indicating a potential upside of 214.12%. Given Caribou Biosciences’ higher probable upside, equities research analysts clearly believe Caribou Biosciences is more favorable than Spyre Therapeutics.

Profitability

This table compares Caribou Biosciences and Spyre Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,800.93%	-62.35%	-49.65%
Spyre Therapeutics	N/A	-71.30%	-38.69%

Institutional & Insider Ownership

77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 9.5% of Caribou Biosciences shares are owned by company insiders. Comparatively, 6.2% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Caribou Biosciences has a beta of 2.54, suggesting that its stock price is 154% more volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.87, suggesting that its stock price is 187% more volatile than the S&P 500.

Valuation and Earnings

This table compares Caribou Biosciences and Spyre Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$9.99 million	17.43	-$149.10 million	($1.78)	-1.05
Spyre Therapeutics	$890,000.00	1,153.71	-$208.02 million	($3.40)	-5.00

Caribou Biosciences has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Spyre Therapeutics beats Caribou Biosciences on 8 of the 15 factors compared between the two stocks.

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

About Spyre Therapeutics

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.